Shift Pharmaceuticals Completes CMT Research Foundation-Funded Project, Will Continue Development of Gene Therapy for CMT1A
By Keith Fargo, Chief Scientific Officer The CMT Research Foundation is pleased to announce that Shift Pharmaceuticals (Shift) has successfully completed their CMT Research Foundation-funded RNA-based therapy project. Shift created and tested a library of novel...The Power of Scientific Collaboration – New Biomarkers for CMT
By Keith Fargo, Chief Scientific Officer At the CMT Research Foundation, we believe that more is achieved when people work together than when they work individually. This is especially true in biomedical research. Over the past few decades, a seismic shift has...CMTRF Research Efforts to Benefit from a Portion of Ticket Sales from Alan Jackson’s Last Call: One More for the Road Tour
ATLANTA (March 11, 2022) CMT Research Foundation (CMTRF) the only nonprofit organization focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, will see its efforts boosted by country music superstar Alan Jackson’s fans this...Maximiliano Barrientos Joins CMT Research Foundation
The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease* is pleased to announce that Maximiliano Barrientos has joined its Board of Directors. Mr. Barrientos is a Co-founder, Investor and CFO...Welcoming New Expert Advisors
By Keith Fargo, Chief Scientific Officer The CMT Research Foundation’s Scientific Advisory Board is composed of distinguished scientists and clinicians who provide independent expert perspectives as key volunteers. Their contributions take several forms. Most visibly,...
Important Research News Announcements
- A translatable RNAi-driven gene therapy silences PMP22/Pmp22 genes and improves neuropathy in CMT1A mice May 17, 2022
- Original Surgical Treatment and Long-term Follow-up for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Causing A Compressive Cervical Myelopathy May 17, 2022
- Structural insights into Charcot-Marie-Tooth disease-linked mutations in human GDAP1 May 5, 2022
- Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice May 2, 2022
- Determine the Safety and Dose of EN001 in Patients With Charcot-Marie-Tooth Disease Type 1A April 19, 2022
- Generation of a human induced pluripotent stem cell (iPSC) line (JUCTCi019-A) from a patient with Charcot-Marie-Tooth disease type 2A2 (CMT2A2) due to a heterozygous missense substitution c.2119C > T (p.Arg707Trp) in MFN2 gene April 12, 2022
- Dosage effects of PMP22 on nonmyelinating Schwann cells in hereditary neuropathy with liability to pressure palsies April 9, 2022
- The Antiepileptic Valproic Acid Ameliorates Charcot-Marie-Tooth 2W (CMT2W) Disease-Associated HARS1 Mutation-Induced Inhibition of Neuronal Cell Morphological Differentiation Through c-Jun N-terminal Kinase April 5, 2022
- Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor March 30, 2022
- Curcumin and Ethanol Effects in Trembler-J Schwann Cell Culture March 29, 2022
